Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in...
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech ...
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities...
/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Moderna is expected to announce its fiscal first-quarter earnings next month, and analysts project a high single-digit decline in losses.
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:...
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery...
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized,...